Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2021-11-12 00:00:00 ET · period of report 2021-11-12 · accession 0000886163-21-000134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-12 | 2021-11-12 | LGND | HIGGINS JOHN L | CEO, Dir | S - Sale | $160.50 | -3,000 | 335.1K | -0.9% | -$481.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-12 | S | D | 3,000 | $160.50 | 335,095 | D | — | — |